WO2006129058A3 - Screening and treatment of alzheimer's disease - Google Patents

Screening and treatment of alzheimer's disease Download PDF

Info

Publication number
WO2006129058A3
WO2006129058A3 PCT/GB2006/001850 GB2006001850W WO2006129058A3 WO 2006129058 A3 WO2006129058 A3 WO 2006129058A3 GB 2006001850 W GB2006001850 W GB 2006001850W WO 2006129058 A3 WO2006129058 A3 WO 2006129058A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
disease
screening
treatment
snp
Prior art date
Application number
PCT/GB2006/001850
Other languages
French (fr)
Other versions
WO2006129058A2 (en
Inventor
Lesley Jones
Michael O'donovan
Stephen Mcllroy
Original Assignee
Univ Cardiff
Mcllroy Esther
Lesley Jones
Michael O'donovan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff, Mcllroy Esther, Lesley Jones, Michael O'donovan filed Critical Univ Cardiff
Publication of WO2006129058A2 publication Critical patent/WO2006129058A2/en
Publication of WO2006129058A3 publication Critical patent/WO2006129058A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method and means for diagnosing the susceptibility to, or existence of, Alzheimer's Disease involving examining the CHAT gene promoter region for SNP rs733722.
PCT/GB2006/001850 2005-05-28 2006-05-19 Screening and treatment of alzheimer's disease WO2006129058A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0511003A GB0511003D0 (en) 2005-05-28 2005-05-28 Screening and treatment of alzheimer's disease
GB0511003.6 2005-05-28

Publications (2)

Publication Number Publication Date
WO2006129058A2 WO2006129058A2 (en) 2006-12-07
WO2006129058A3 true WO2006129058A3 (en) 2007-02-01

Family

ID=34834847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001850 WO2006129058A2 (en) 2005-05-28 2006-05-19 Screening and treatment of alzheimer's disease

Country Status (2)

Country Link
GB (1) GB0511003D0 (en)
WO (1) WO2006129058A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116666A1 (en) * 2013-01-22 2014-07-31 Courtagen Life Sciences, Inc. Methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065489A1 (en) * 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065489A1 (en) * 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COOK LYNNETTE J ET AL: "Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study.", AMERICAN JOURNAL OF MEDICAL GENETICS. PART B, NEUROPSYCHIATRIC GENETICS : THE OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY OF PSYCHIATRIC GENETICS. 5 JAN 2005, vol. 132, no. 1, 5 January 2005 (2005-01-05), pages 5 - 8, XP002404461, ISSN: 1552-4841 *
HAROLD DENISE ET AL: "Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease.", HUMAN GENETICS. AUG 2003, vol. 113, no. 3, August 2003 (2003-08-01), pages 258 - 267, XP002404460, ISSN: 0340-6717 *
TURIC D ET AL: "P4-090 Evidence of association with late onset Alzheimer's disease on chromosome 10Q", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 25, July 2004 (2004-07-01), pages S500, XP004626262, ISSN: 0197-4580 *

Also Published As

Publication number Publication date
GB0511003D0 (en) 2005-07-06
WO2006129058A2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
WO2007047408A3 (en) Promac signature application
EP1904630A4 (en) Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
IL225203A (en) Isolated complement factor h polypeptide, means for its preparation, uses thereof and an agent that reduces its expression or activity
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
EP1948831A4 (en) Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
ZA200707230B (en) Method of prognosis of mental diseases, e.g. autism and cerebral palsy
EP1990374A4 (en) C. i. pigment red 57:1 and method for producing the same
WO2006122046A3 (en) Vascular disease therapies
EP1858399A4 (en) Methods for diagnosis and treatment of processing difficulties, integration problems, imbalances and abnormal postures
WO2007056435A3 (en) Dynamin mediated diseases and associated methods and products
WO2007038264A3 (en) Gapr-1 methods
IL190585A0 (en) Method for the diagnosis of thromboembolic and coronary heart diseases
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007063405A3 (en) Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes using human cel gene
GB0518916D0 (en) Treating commodities against unwanted biological activity
WO2006129058A3 (en) Screening and treatment of alzheimer's disease
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
EP1883628A4 (en) Improved process for the preparation of 3,5-diethyl-1,2-dihydro-1-phenyl-2-propylpyridine
WO2005072241A3 (en) Inhibition of bright function as a treatment for excessive immunoglobulin production

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06727140

Country of ref document: EP

Kind code of ref document: A2